Cameron Turtle - 09 Jan 2026 Form 4 Insider Report for Spyre Therapeutics, Inc. (SYRE)

Role: Chief Executive Officer, Director
Signature: /s/ Heidy King-Jones, as Attorney-in-Fact
Issuer symbol: SYRE
Transactions as of: 09 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 13 Jan 2026, 21:27:08 UTC
Previous filing: 06 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Turtle Cameron	Chief Executive Officer, Director	221 CRESCENT STREET, BUILDING 23,, SUITE 105, WALTHAM	/s/ Heidy King-Jones, as Attorney-in-Fact	13 Jan 2026	0001758363

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SYRE	Stock Option (Right to Buy)	Award	$0	+528,000		$0.000000	528,000	09 Jan 2026	Common Stock	528,000	$30.61	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option represents a right to purchase 528,000 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date.